E. Ibler

Multiple sclerosis association with psoriasis: a large U.S. population, single centre, retrospective cross-sectional study

cutaneous vasculitis and arthritis. Possible immune complex syndrome. Mayo Clin Proc 1973; 48: 340–348. 5 Messiaen T, Van Damme B, Kuypers D, Maes B, Vanrenterghem Y. Crescentic glomerulonephritis complicating the course of a hypocomplementemic urticarial vasculitis. Clin Nephrol 2000; 54: 409–412. 6 Grotz W, Baba H, Becker J et al. Hypocomplementemic urticarial vasculitis syndrome. An interdisciplinary challenge. Dtsch Arztebl Int 2009; 106: 756–763. 7 Mehregan D, Hall M, Gibson L. Urticarial vasculitis? A histopathological and clinical review of 72 cases. J Am Acad Dermatol 1992; 26: 441–448. 8 Aydogan K, Karadogan S, Adim S et al. Hypocomplementemic urticarial vasculitis: a rare presentation of systemic lupus erythematosus. Int J Dermatol 2006; 45: 1057–1061. 9 Ghazanfar MN, Thomsen SF. Omalizumab for urticarial vasculitis: case report and review of the literature. Case Rep Dermatol Med 2015; 2015: 576893. 10 Diez LS, Tamayo LM, Cardona R. Omalizumab: therapeutic option in chronic spontaneous urticaria difficult to control with associated vasculitis, report of three cases. Biomedica 2013; 33: 503–512. 11 Kaplan AP, Gim enez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy 2017; 72: 519–533.

Rosacea and subsequent diagnosis for Parkinson's disease: a large, urban, single center, US patient population retrospective study

U.N. Saikia, R. Kapoor, R.S. Mavuduru Department of Dermatology, Venereology and Leprology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Radiotherapy, Post Graduate Institute of Medical Education and Research, Chandigarh, India, Urology, Post Graduate Institute of Medical Education and Research, Chandigarh, India *Correspondence: T. Narang. E-mail: narangtarun@yahoo.co.in

Inverse association for diagnosis of Alzheimer's disease subsequent to both melanoma and non-melanoma skin cancers in a large, urban, single-centre, Midwestern US patient population

Although literature demonstrates a decreased risk of Alzheimers disease (AD) in individuals with various cancers, including squamous cell cancers (SCC) and basal cell cancers (BCC) comprising non‐melanoma skin cancers (NMSC), there is a paucity of literature to substantiate an association between malignant melanoma (MM) and AD.

Malignant melanoma associated with chronic once daily aspirin exposure in males: a large, single-center, urban, U.S. patient population cohort study from the Research on Adverse Drug events And Reports (RADAR) project

To the Editor: Conflicting evidence exists for the risk of malignant melanoma (MM) subsequent to chronic aspirin exposure. Although a study in the Journal of the American Academy of Dermatology demonstrated that chronic aspirin exposure before and after MM diagnosis in a large midwestern US population was associated with overall prolonged survival, the risk of MM subsequent to chronic aspirin exposure remains uncertain. The aim of this study, which was also conducted within a large midwestern US patient population, was to determine whether there was a detectable risk for MM after 1 year or more of chronic aspirin exposure. Using the methodology of the ‘‘Research on Adverse Drug events And Report’’, the Northwestern Medicine Enterprise Data Warehouse,

Hidradenitis suppurativa association at the time of, or subsequent to, diagnosis of inflammatory bowel disease in a large U.S. patient population

associated with milder skin symptoms. We report the case of a woman affected by atopic dermatitis and asthma in childhood who developed at the age of 63 years conjunctivitis associated with blepharitis without causative contact allergen identification at skin testing. She received multiple topical and systemic treatments including cyclosporine 2 mg/kg/ day stopped after 4 days because of digestive adverse effects. She was examined at the age of 72 years for severe ulcerated keratoconjunctivitis complicated of corneal ulcers with reduced visual acuity, justifying the introduction of azathioprine (AZ) 100 mg/ day. Ulceration and keratitis improved, but one year later, a papulopustular eruption on the face led to the clinical and pathological diagnosis of rosacea (Fig. 1). Under doxycycline 200 mg/day, lesions disappeared in 4 weeks and doxycycline was tapered to 50 mg/day in the following 3 months. Although not described as rosacea trigger, AZ was strongly suspected, and AZ dosing was progressively decreased over 3 months. At 25 mg AZ/day, keratoconjunctivitis relapsed requiring to increase AZ doses. Milder rosacea relapses were observed when AZ was increased to 50 mg/day. After a year under careful ophthalmological and dermatological monitoring, a maintenance dose of 50 mg alternating with 25 mg/day AZ was found able to control keratoconjunctivitis and blepharitis, without recurring signs of rosacea. Overall, AZ was helpful to control severe atopic keratoconjunctivitis, but triggered rosacea with a dose–response effect. This observation highlights that skin symptoms in a person under AZ for atopic keratoconjunctivitis can be caused by other disorders than AD, such as rosacea, and that AZ-induced rosacea, although possibly rare or underreported, exists. A statement of all funding sources that supported the work: 1. V edie A-L, Ezzedine K, Amazan E, Boralevi F, Milpied B, Ta€ıeb A, et al. Long-Term Use of Systemic Treatments for Moderate-to-Severe Atopic Dermatitis in Adults: A Monocentric Retrospective Study. Acta Derm Venereol. 2016 Mar 1.

Rate of serious infection in patients who are prescribed systemic biologic or nonbiologic agents for psoriasis: A large, single center, retrospective, observational cohort study

Systemic biologic and nonbiologic agents used to treat psoriasis may or may not contribute to serious infection (SI) risk. Safety data, particularly for biologic agents, and associated risk for SI, are scarce. The studys aim was to explore the risk for SI in psoriasis patients exposed to systemic biologic or nonbiologic agents.